世界胃肠药理与治疗学杂志:英文版(电子版)最新文献

{"title":"Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies.","authors":"Ayrton Bangolo, Behzad Amoozgar, Maryam Habibi, Elizabeth Simms, Vignesh K Nagesh, Shruti Wadhwani, Nikita Wadhwani, Auda Auda, Daniel Elias, Charlene Mansour, Robert Abbott, Nisrene Jebara, Lili Zhang, Sarvarinder Gill, Kareem Ahmed, Andrew Ip, Andre Goy, Christina Cho","doi":"10.4292/wjgpt.v16.i2.105375","DOIUrl":"10.4292/wjgpt.v16.i2.105375","url":null,"abstract":"<p><strong>Background: </strong>Anemia is a prevalent and challenging complication in patients with hematologic and solid malignancies, which stems from the direct effects of malignancy, treatment-induced toxicities, and systemic inflammation. It affects patients' survival, functional status, and quality of life profoundly. Recent literature has highlighted the emerging role of the gut microbiome in the pathogenesis of cancer-associated anemia. The gut microbiota, through its intricate interplay with iron metabolism, inflammatory pathways, and immune modulation, may either exacerbate or ameliorate anemia depending on its composition, and functional integrity. Dysbiosis, characterized by disruption in the gut microbial ecosystem, is very common in cancer patients. This microbial imbalance is implicated in anemia causation through diminished iron absorption, persistent low-grade inflammation, and suppression of erythropoiesis.</p><p><strong>Aim: </strong>To consolidate current evidence regarding the interplay between gut microbiome and anemia in the setting of malignancies. It aims to provide a detailed exploration of the mechanistic links between dysbiosis and anemia, identifies unique challenges associated with various cancer types, and evaluates the efficacy of microbiome-focused therapies. Through this integrative approach, the review seeks to establish a foundation for innovative clinical strategies aimed at mitigating anemia and improving patient outcomes in oncology.</p><p><strong>Methods: </strong>A literature search was performed using multiple databases, including Google Scholar, PubMed, Scopus, and Web of Science, using a combination of keywords and Boolean operators to refine results. Keywords included \"cancer-associated anemia\", \"gut microbiome\", \"intestinal microbiota\", \"iron metabolism\", \"gut dysbiosis\", \"short-chain fatty acids\", \"hematopoiesis\", \"probiotics\", \"prebiotics\", and \"fecal microbiota transplantation\". Articles published in English between 2000 and December 2024 were included, with a focus on contemporary and relevant findings.</p><p><strong>Results: </strong>Therapeutic strategies aimed at restoration of gut microbial homeostasis, such as probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT), can inhibit anemia-causing pathways by enhancing microbial diversity, suppressing detrimental flora, reducing systemic inflammation and optimizing nutrient absorption.</p><p><strong>Conclusion: </strong>Gut dysbiosis causes anemia and impairs response to chemotherapy in cancer patients. Microbiome-centered interventions, such as probiotics, prebiotics, dietary modifications, and FMT, have shown efficacy in restoring microbial balance, reducing inflammation, and enhancing nutrient bioavailability. Emerging approaches, including engineered probiotics and bacteriophage therapies, are promising precision-based, customizable solutions for various microbiome compositions and imbalances. Future research ","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"105375"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opioid analgesics for sedation-based gastrointestinal endoscopy.","authors":"Wei-Lin Yang, Xin-Yu Zhou, Wen-Cai Jiang, Xian-Jie Zhang, Dan Zhou","doi":"10.4292/wjgpt.v16.i2.102098","DOIUrl":"10.4292/wjgpt.v16.i2.102098","url":null,"abstract":"<p><p>Gastrointestinal endoscopy is a common examination for digestive system. The stimulation of endoscope often causes cough, nausea and vomiting, increased heart rate and blood pressure, arrhythmia, and even cardiovascular and cerebrovascular accidents, thus makes people fear of this procedure. Sedation or anesthesia can effectively improve the safety, comfort and quality of gastrointestinal endoscopy. A small dose of opioids is a good adjuvant to sedatives. In this narrative review, we summarized the main roles of opioid analgesics in gastrointestinal endoscopy, including reducing visceral pain, throat irritation and the dose of sedatives. Moreover, the frequently used and novel opioids are reviewed. Classic fentanyl, sufentanil and dezocine are preferable by anesthesiologists. Newly approved oliceridine is promising to render ideal analgesic effects for gastrointestinal endoscopy. Clinical studies on oliceridine in endoscopic procedures are urgently needed.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"102098"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation (train-IBD trial).","authors":"Anne Fennessy, Micheal Doyle, Anna Boland, Rachel Bourke, Anthony O'Connor","doi":"10.4292/wjgpt.v16.i2.101268","DOIUrl":"10.4292/wjgpt.v16.i2.101268","url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) symptoms are common in patients with inflammatory bowel disease (IBD), with systematic review reporting an overall pooled prevalence of 35-39% in patients with clinical remission. This subset of patients reports a reduced quality of life and increased anxiety and depression. A multi-strain probiotic (Symprove™, Symprove Ltd, Farnham, United Kingdom) has been shown to improve overall symptom severity in patients with IBS and is associated with decreased intestinal inflammation in patients with ulcerative colitis (UC), but not in Crohn's disease (CD).</p><p><strong>Aim: </strong>To ascertain whether this multi-strain probiotic would be effective in an IBS/IBD overlap population.</p><p><strong>Methods: </strong>The treatment of symptoms in the absence of inflammation in inflammatory bowel diseases trial was a randomized, double-blind, placebo-controlled trial of a four-strain probiotic Symprove, containing Lactobacillus rhamnosus NCIMB 30174, Lactobacillus plantarum NCIMB 30173, Lactobacillus acidophilus NCIMB 30175 and Enterococcus faecium NCIMB 30176. The duration of the study was 3 months, at the end of which IBS-Symptom Severity Score (IBS-SSS) was repeated. Primary Endpoint was a 100-point reduction in IBS-SSS.</p><p><strong>Results: </strong>61 participants were randomized into the intention-to-treat analysis. 45% of patients receiving the active agent achieved the endpoint compared to 33% of those receiving placebo (<i>P</i> = 0.42). In UC, 50% of patients receiving placebo achieved the endpoint compared to 44% of those receiving the active agent (<i>P</i> = 1.00). In CD 45% of those receiving the active agent achieved the endpoint compared to 29% of those receiving placebo (<i>P</i> = 0.34). The mean change in IBS-SSS for patients receiving placebo was a reduction of 61 points, compared to a reduction in 90 points for patients receiving active agent (<i>P</i> = 0.31). There was no difference between the groups with regard to IBD outcomes.</p><p><strong>Conclusion: </strong>Probiotics may represent a safe and effective means of addressing the unmet clinical need for symptom relief in patients with overlapping IBS and IBD, especially in those with CD.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"101268"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidities and systemic steroids drive pneumonia risk in inflammatory bowel disease: Propensity score-matched cohort study.","authors":"Yong Eun, Joan Culpepper-Morgan, Abiodun M Akanmode, Myint B Thu, Aprilee A Sta Lucia, Marie S Thearle, Rhonda K Trousdale","doi":"10.4292/wjgpt.v16.i2.105335","DOIUrl":"10.4292/wjgpt.v16.i2.105335","url":null,"abstract":"<p><strong>Background: </strong>Patients with inflammatory bowel disease (IBD) are at an increased risk of bacterial pneumonia, contributing to significant morbidity and mortality. While previous studies have identified various risk factors, including medications and comorbidities, the independent contribution of IBD to pneumonia risk remains unclear. We hypothesized that the increased pneumonia risk is primarily driven by factors other than IBD itself.</p><p><strong>Aim: </strong>To investigate the relative contributions of IBD, comorbidities, and medications to pneumonia risk in patients with IBD.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the All of Us Research Program database (2010-2022). We matched 2810 participants with IBD 1:1 with controls using four propensity score models: (1) Demographics/Lifestyle only; (2) Plus comorbidities; (3) Plus medications; and (4) All factors combined. Then we used Cox proportional hazards models to assess pneumonia risk and logistic regression to evaluate risk factors.</p><p><strong>Results: </strong>In the primary analysis of 5620 matched participants, IBD was not independently associated with increased pneumonia risk [hazard ratio (HR) = 1.07, 95%CI: 0.84-1.35] when matched for all factors. However, participants with IBD had significantly higher risk (HR = 2.08, 95%CI: 1.56-2.78) when matched only for demographics and lifestyle factors. Within the IBD cohort, a high comorbidity burden (Charlson Comorbidity Index ≥ 10) [odds ratio (OR) = 12.20, 95%CI: 6.69-23.00] and systemic steroid use (OR = 2.26, 95%CI: 1.21-4.64) were independently associated with increased pneumonia risk.</p><p><strong>Conclusion: </strong>Comorbidities and systemic steroids, rather than IBD itself, drive pneumonia risk. Management should focus on these factors and prioritize vaccination in high-risk patients.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"105335"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of elobixibat for elderly patients with chronic constipation in a clinic.","authors":"Yuji Sakai, Toshio Tsuyuguchi, Junichiro Kumagai, Hiroshi Ohyama, Takashi Kaiho, Masayuki Ohtsuka, Naoya Kato","doi":"10.4292/wjgpt.v16.i2.105801","DOIUrl":"10.4292/wjgpt.v16.i2.105801","url":null,"abstract":"<p><strong>Background: </strong>Elobixibat reportedly improves bowel movements in patients with chronic constipation. However, its effect on bowel movements in elderly patients with chronic constipation in clinical settings has not been examined.</p><p><strong>Aim: </strong>To examine bowel movement frequency and stool form before and after elobixibat administration in elderly patients with chronic constipation at our clinic.</p><p><strong>Methods: </strong>A total of 10 mg elobixibat was administered to 35 (< 65 years old) patients and 45 (≥ 65 years old) patients with chronic constipation. The frequency of bowel movements and stool forms, assessed using the Bristol Stool Form Scale (BSFS), were compared between the two groups 1 week before and after elobixibat administration.</p><p><strong>Results: </strong>In patients aged < 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.167 ± 0.732 and 2.286 ± 0.742, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 2.389 ± 0.502 and 3.995 ± 0.566, respectively, showing a significant improvement in bowel movement status. In patients aged ≥ 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.003 ± 0.733 and 2.217 ± 0.758, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 4.402 ± 1.346 and 3.800 ± 0.704, respectively, indicating an improvement in bowel movement status (<i>P</i> < 0.001). No significant differences were observed in the frequency and improvement status of bowel movements or BSFS scores between patients with chronic constipation aged ≥ 65 years and < 65 years. Adverse events due to the administration of elobixibat occurred in 16 cases (20%). No significant differences were found in the incidence of adverse events between patients with chronic constipation aged < 65 years (8 cases, 22.9%) and those aged ≥ 65 years (8 cases, 17.8%).</p><p><strong>Conclusion: </strong>Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"105801"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease characteristics and long-term outcomes of cyclic vomiting syndrome in Singaporean children.","authors":"Lynette Goh, Jeremy Meng Dao Ho, Fang Kuan Chiou","doi":"10.4292/wjgpt.v16.i2.103971","DOIUrl":"10.4292/wjgpt.v16.i2.103971","url":null,"abstract":"<p><strong>Background: </strong>Cyclic vomiting syndrome (CVS) and its effect on nutritional status has not been well described.</p><p><strong>Aim: </strong>To describe the clinical characteristics, treatment and outcomes of children with CVS in Singapore.</p><p><strong>Methods: </strong>Retrospective cohort study of pediatric patients aged 1 to 18 years old with CVS diagnosed at KK Women's and Children's Hospital in Singapore from 2011 to 2021.</p><p><strong>Results: </strong>Thirty-two children (69% female) with CVS were included in the study, with mean age of onset of symptoms at 7 (± 4) years and mean follow up duration of 5 years. Forty percent (12/32) of patients were underweight at diagnosis with no other identifiable organic cause, with a median body mass index (BMI) <i>z</i> score -3.2 (range -2 to -7.5). The incidence of systemic hypertension was 10% (3/32). The overall mean frequency of exacerbations in this cohort of patients was 4 (± 4) episodes per year. In total, 16 (50%) patients, who had mean baseline frequency of 6 (± 5) attacks per year, were commenced on prophylactic treatment. Twelve patients (75%) responded to first-line therapy, whereas 4 (25%) required escalation to second-line treatment. With prophylactic treatment, there was an overall improvement in the frequency of attacks with a mean reduction of 5 (± 3) attacks per year. Also, there was improvement in the BMI <i>z</i> score of these patients from a median of -2.9 to -0.9.</p><p><strong>Conclusion: </strong>Prophylactic treatment is effective in improving nutritional status as well as reducing symptom frequency and should be considered for patients with complications such as growth failure and significant hypertension.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"103971"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotics and prebiotics in the treatment of functional constipation in the elderly individuals.","authors":"Li Xu, Jian-Tang Guo, Jing Zhao, Ming-He Liu, Chen Mo","doi":"10.4292/wjgpt.v16.i2.105242","DOIUrl":"10.4292/wjgpt.v16.i2.105242","url":null,"abstract":"<p><p>Functional constipation (FC) in elderly individuals is a significant health issue that adversely affects their quality of life, with recent studies indicating a close relationship between this condition and gut microbiota dysbiosis. This review aims to explore the role of the gut microbiota in FC in elderly individuals, analyze the mechanisms of the gut-brain axis, and evaluate the potential use of microecological agents, including probiotics and prebiotics, in modulating the gut microbiota and alleviating constipation symptoms. By integrating the latest research findings, this study seeks to provide new perspectives and intervention strategies for the management of FC in elderly individuals.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"105242"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nalbuphine <i>vs</i> sufentanil as effective analgesics for postoperative pain management in gastric cancer resection.","authors":"Wei-Xiang Wang, Fu-Lin Dang, Ting-Ting Li, Yue Yu","doi":"10.4292/wjgpt.v16.i2.103232","DOIUrl":"10.4292/wjgpt.v16.i2.103232","url":null,"abstract":"<p><p>This editorial highlights the randomized controlled trial by Qian <i>et al</i> evaluating the efficacy of nalbuphine in managing postoperative pain and associated inflammatory factors in patients undergoing radical gastrectomy for gastric cancer. Utilizing a multimodal analgesic approach with a controlled analgesia pump and a transverse abdominis muscle plane block, the study compared nalbuphine against sufentanil. Results indicate that nalbuphine significantly reduces pain scores at various postoperative intervals, decreases consumption and patient-controlled analgesia presses, and lowers levels of pain markers such as prostaglandin E2, serotonin, and substance P. While both agents demonstrated effective pain control, nalbuphine was associated with a lower incidence of adverse effects, suggesting its potential as a valuable alternative in appropriate clinical scenarios. This study offers valuable insights into nalbuphine's clinical applicability, underscoring its benefits for pain management and enhancing patient recovery in the postoperative setting.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"103232"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insight into global burden of gastroesophageal reflux disease: Understanding its reach and impact.","authors":"Nilanka Wickramasinghe, Niranga Manjuri Devanarayana","doi":"10.4292/wjgpt.v16.i1.97918","DOIUrl":"https://doi.org/10.4292/wjgpt.v16.i1.97918","url":null,"abstract":"<p><p>The exact worldwide prevalence of gastroesophageal reflux disease (GERD) remains uncertain, despite its recognition as a common condition. This conundrum arises primarily from the lack of a standardized definition for GERD. The gold standard diagnostic tests for GERD, such as pH impedance testing and endoscopy, are cumbersome and impractical for assessing community prevalence. Consequently, most epidemiological studies rely on symptom-based screening tools. GERD symptoms can be both esophageal and extraesophageal, varying widely among individuals. This variability has led to multiple symptom-based definitions of GERD, with no consensus, resulting in prevalence estimates ranging from 5% to 25% worldwide. Most systematic reviews define GERD as experiencing heartburn and/or regurgitation at least once weekly, yielding a calculated prevalence of 13.98%. In 2017, the global age-standardized prevalence of GERD was estimated at 8819 per 100000 people (95% confidence interval: 7781-9863), a figure that has remained stable from 1990 to 2017. Prevalence increases with age, leading to more years lived with disability. GERD significantly impairs quality of life and can lead to multiple complications. Additionally, it imposes a severe economic burden, with the United States alone estimated to spend around 10 billion dollars annually on diagnosis and treatment. In summary, GERD prevalence varies greatly by region and even within different areas of the same province. Determining the exact prevalence is challenging due to inconsistent diagnostic criteria. However, it is well-documented that GERD poses a significant global burden, affecting the quality of life of individuals and creating a substantial healthcare cost.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 1","pages":"97918"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease.","authors":"Parimal Lawate, Virender Chauhan, Lingampalli Rajendra Prasad, Abhimanrao Pawar, Atul G Puranik, Alok Bansal, Abhiram Koganti, Ashok Jaiswal, Pranali Puradkar, Kunal Jhaveri","doi":"10.4292/wjgpt.v16.i1.103898","DOIUrl":"https://doi.org/10.4292/wjgpt.v16.i1.103898","url":null,"abstract":"<p><strong>Background: </strong>Abnormal gastric acid reflux into the esophagus causes symptoms of gastroesophageal reflux disease (GERD) such as heartburn and regurgitation and also leads to mucosal damage. This damage can further lead to complications such as Barrett's esophagus and esophagitis. Conventional proton pump inhibitors (PPIs) often fail to reduce nocturnal acid production, leaving patients with unresolved symptoms that worsen at night and decreased satisfaction. Happi ER, a novel dual delayed-release (DDR) formulation of rabeprazole, aims to address these limitations by providing both immediate and prolonged acid suppression.</p><p><strong>Aim: </strong>To evaluate the safety and effectiveness of rabeprazole DDR 20 mg capsule in patients with GERD.</p><p><strong>Methods: </strong>This study involved a multicenter, real-world, prospective, observational design over an eight-week period. A total of 1022 GERD patients were treated with rabeprazole DDR 20 mg capsules (Happi ER), as prescribed by their physicians. We included adult patients with confirmed GERD and persistent heartburn symptoms despite prior PPI use. Outcome measures included heartburn severity, frequency of night-time awakenings, use of rescue medications, and overall patient satisfaction.</p><p><strong>Results: </strong>Rabeprazole DDR 20 mg capsules (Happi ER) were shown to be highly effective in treating GERD symptoms. At the end of the study, the mean heartburn score improved significantly from 2.46 ± 0.67 at baseline to 0.16 ± 0.39 (<i>P</i> < 0.0001). The median number of night-time awakenings decreased to 0 (<i>P</i> < 0.0001). More than 93% of patients rated the therapy as \"excellent\" or \"very good\", reflecting high satisfaction. No significant adverse effects were reported, and the safety profile was comparable to that of traditional PPIs.</p><p><strong>Conclusion: </strong>By providing both rapid and sustained acid suppression, Happi ER effectively treats GERD, particularly with respect to night-time symptoms. Its safety and efficacy profile make it a viable option for individuals with mild-to-moderate GERD, significantly improving the quality of life and symptom management.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 1","pages":"103898"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}